Cargando…

Complete response induced by fotemustine given as single agent in a patient with primary central nervous system non-Hodgkin aggressive lymphoma relapsed after high-dose chemotherapy and autologous stem cell support

Detalles Bibliográficos
Autores principales:	Pennese, Elsa, Vergine, Carolina, Matera, Rosella, Dargenio, Michela, Forese, Pasquale, Di Renzo, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Informa Healthcare 2011
Materias:	Letter to The Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3211192/ https://www.ncbi.nlm.nih.gov/pubmed/21718140 http://dx.doi.org/10.3109/10428194.2011.585672

Ejemplares similares

Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine‐based high‐dose chemotherapy regimen
por: Musso, Maurizio, et al.
Publicado: (2015)

A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010)

Erratum to: A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010)

Treatment of Hodgkin Lymphoma Relapsed after Autologous Stem Cell Transplantation
por: Domingo-Domènech, Eva, et al.
Publicado: (2020)

Current Role of Autologous and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
por: Castagna, Luca, et al.
Publicado: (2015)

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma
por: Forlenza, Christopher J., et al.
Publicado: (2023)

Central Nervous System Toxoplasmosis in Relapsed Hodgkin’s Lymphoma: A Case Report
por: Abolghasemi, Hassan, et al.
Publicado: (2016)

The Combination of Carmustine Wafers and Fotemustine in Recurrent Glioblastoma Patients: A Monoinstitutional Experience
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
por: Fazeny-Dörner, B, et al.
Publicado: (2003)

Regulation of Inflammatory and Proliferative Pathways by Fotemustine and Dexamethasone in Endometriosis
por: Genovese, Tiziana, et al.
Publicado: (2021)

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant
por: Tun, Aung M., et al.
Publicado: (2023)

Aggressive Central Nervous System Relapse after Autologous Stem Cell Transplant in Multiple Myeloma: Case Reports and Literature Review
por: Bergantim, Rui, et al.
Publicado: (2020)

Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas
por: Corazzelli, Gaetano, et al.
Publicado: (2011)

Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas
por: Volpetti, Stefano, et al.
Publicado: (2014)

Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation
por: Kaloyannidis, Panayotis, et al.
Publicado: (2019)

Outcomes of Refractory and Relapsed Hodgkin Lymphoma With Autologous Stem-Cell Transplantation: A Single Institution Experience
por: Wali, Rabia, et al.
Publicado: (2019)

Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective
por: Sureda, Anna, et al.
Publicado: (2020)

Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018)

Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas
por: Vaccaro, V., et al.
Publicado: (2014)

Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin’s lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation
por: Di Renzo, Nicola, et al.
Publicado: (2021)

Role of Consolidative Radiation Therapy After Autologous Hematopoietic Cell Transplantation for the Treatment of Relapsed or Refractory Hodgkin Lymphoma
por: Wilke, Christopher, et al.
Publicado: (2017)

Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma
por: Zhang, Chen, et al.
Publicado: (2023)

Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
por: Lee, S. M., et al.
Publicado: (1993)

Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma
por: Santoni, Matteo, et al.
Publicado: (2013)

Fotemustine: A Third-Generation Nitrosourea for the Treatment of Recurrent Malignant Gliomas
por: Beauchesne, Patrick
Publicado: (2012)

Outcomes in relapsed Hodgkin's lymphoma treated with autologous and allogeneic hematopoietic cell transplantation at the Pontificia Universidad Católica de Chile
por: Ramirez, Pablo, et al.
Publicado: (2015)

Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma
por: Mangiacavalli, Silvia, et al.
Publicado: (2013)

Hodgkin’s lymphoma: post- autologous transplantation consolidation therapy
por: Merli, Francesco, et al.
Publicado: (2020)

Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2
por: Becker, J C, et al.
Publicado: (2002)

An Overview of Fotemustine in High-Grade Gliomas: From Single Agent to Association with Bevacizumab
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

Retrospective Analysis of Bevacizumab in Combination with Fotemustine in Chinese Patients with Recurrent Glioblastoma Multiforme
por: Liu, Zhiguang, et al.
Publicado: (2015)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma
por: Makita, Shinichi, et al.
Publicado: (2022)

Autologous Stem Cell Transplantation for Aggressive Lymphomas
por: Visani, Giuseppe, et al.
Publicado: (2012)

Mediastinal Choriocarcinoma Masquerading as Relapsed Hodgkin Lymphoma
por: Lam, Selay, et al.
Publicado: (2011)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

Non-Hodgkin lymphoma with relapses in the lacrimal glands
por: Couceiro, Rita, et al.
Publicado: (2015)

New agents in relapsed/refractory Hodgkin's lymphoma()
por: Biasoli, Irene, et al.
Publicado: (2017)

Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant
por: Nieto, Yago, et al.
Publicado: (2023)

Cellular function given parametric variation in the Hodgkin and Huxley model of excitability
por: Ori, Hillel, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_f61gs17kojam8idj5qu6dqqo8v